How has been the historical performance of Astrazeneca Phar?
Astrazeneca Phar has shown strong financial growth, with net sales increasing from 728.29 Cr in Mar'19 to 1,716.29 Cr in Mar'25, and operating profit rising from 87.58 Cr to 294.60 Cr in the same period. However, profit before tax peaked in Mar'24 and then declined, while total assets grew significantly from 691.72 Cr to 1,476.56 Cr.
Answer:The historical performance of Astrazeneca Phar shows a significant upward trend in net sales and operating profit over the years, with net sales increasing from 728.29 Cr in Mar'19 to 1,716.29 Cr in Mar'25. The total operating income followed a similar trajectory, rising from 728.29 Cr in Mar'19 to 1,716.29 Cr in Mar'25. Operating profit (PBDIT) also saw substantial growth, climbing from 87.58 Cr in Mar'19 to 294.60 Cr in Mar'25. However, profit before tax peaked in Mar'24 at 219.54 Cr before dropping to 156.36 Cr in Mar'25, while profit after tax decreased from 161.51 Cr in Mar'24 to 115.74 Cr in Mar'25. The company's total assets increased from 691.72 Cr in Mar'20 to 1,476.56 Cr in Mar'25, reflecting a robust growth in current assets, particularly inventories and cash. The book value per share also improved significantly, reaching 308.14 in Mar'25 from 145.78 in Mar'20.Breakdown:
Astrazeneca Phar has demonstrated strong growth in its financial metrics over the years. Net sales surged from 728.29 Cr in Mar'19 to 1,716.29 Cr in Mar'25, indicating a consistent upward trend. Total operating income mirrored this growth, reaching 1,716.29 Cr in Mar'25. Operating profit (PBDIT) increased significantly from 87.58 Cr in Mar'19 to 294.60 Cr in Mar'25, although profit before tax saw a peak in Mar'24 at 219.54 Cr before declining to 156.36 Cr in Mar'25. Profit after tax also decreased from 161.51 Cr in Mar'24 to 115.74 Cr in Mar'25. The total assets of the company rose from 691.72 Cr in Mar'20 to 1,476.56 Cr in Mar'25, driven by increases in current assets such as inventories and cash. The book value per share improved notably, reaching 308.14 in Mar'25 from 145.78 in Mar'20, reflecting the company's strengthening financial position.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
